Efficacy and Safety of an Attenuated-Dose Sunitinib Regimen in Metastatic Renal Cell Carcinoma: Results from a Prospective Registry in Singapore

Hui Shan Tan, Huihua Li, Yu Wen Hong, Chee Keong Toh, Alvin Wong, Gilberto Lopes, Miah Hiang Tay, Alexandre Chan, Xin Yao, Tiffany Tang, Quan Sing Ng, Ravindran Kanesvaran, Noan Minh Chau, Min Han Tan

Research output: Contribution to journalArticle

Abstract

Background The use of sunitinib at conventional doses (50 mg/d, 6-week cycles: 4 weeks of treatment, then 2 weeks of no treatment) in Asian patients with metastatic renal cell carcinoma (mRCC) is associated with high real-world toxicities. Patients and Methods Patients with mRCC treated with sunitinib between 2005 and 2012 at 4 centers representing a near-national cohort (n = 160) in Singapore were evaluated. One hundred twenty-seven consecutive patients in 1 center were treated with a novel attenuated-dose sunitinib regimen (37.5 mg/d, 6-week cycle: 4 weeks of treatment, then 2 weeks of no treatment) with outcomes captured in a prospective registry. Efficacy and safety outcomes of these patients were compared against those who received sunitinib at conventional dosing (n = 33) at all 4 centers. Statistical modeling was adjusted for baseline prognostic criteria and therapy line where possible. Results Overall survival from treatment initiation (OSinitiation), overall survival from the first documented metastasis (OStotal), and progression-free survival (PFS) were similar for patients who received first-line sunitinib for conventional relative to attenuated dose regimens (OSinitiation: 18.3 vs. 16.5 months, respectively; P =.54; OStotal: 27.4 vs. 21.8 months, respectively; P =.45; PFS: 6.7 vs. 7.9 months, respectively; P =.64), similar to real-world outcomes in Western studies. A marked lower rate of severe toxicities, dose delays, and reductions were observed with the attenuated dose regimen, with 75/127 (59%), rather than 28/33 (85%) for the conventional dose arm who experienced Grade ≤ 3 toxicities (P =.0088); 31/127 (24%) rather than 19/33 (58%) who experienced dose delays (P =.0004); and 44/127 (35%) rather than 23/33 (70%) who experienced dose reduction (P =.0005) during their course of treatment. Conclusion An attenuated dose regimen of sunitinib yielded comparable real-world efficacy outcomes, with considerable reduction in toxicities as documented in a prospective registry.

Original languageEnglish (US)
Pages (from-to)e285-e295
JournalClinical Genitourinary Cancer
Volume13
Issue number4
DOIs
StatePublished - Aug 1 2015

Keywords

  • Dose modification
  • Kidney cancer
  • Pharmacokinetics
  • Real-world outcomes
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Urology

Fingerprint Dive into the research topics of 'Efficacy and Safety of an Attenuated-Dose Sunitinib Regimen in Metastatic Renal Cell Carcinoma: Results from a Prospective Registry in Singapore'. Together they form a unique fingerprint.

  • Cite this

    Tan, H. S., Li, H., Hong, Y. W., Toh, C. K., Wong, A., Lopes, G., Tay, M. H., Chan, A., Yao, X., Tang, T., Ng, Q. S., Kanesvaran, R., Chau, N. M., & Tan, M. H. (2015). Efficacy and Safety of an Attenuated-Dose Sunitinib Regimen in Metastatic Renal Cell Carcinoma: Results from a Prospective Registry in Singapore. Clinical Genitourinary Cancer, 13(4), e285-e295. https://doi.org/10.1016/j.clgc.2014.11.004